Author

A. N. Alilin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1

Frequent Co-Authors

K. Kelly· 4 shared S. Agarwal· 4 shared A. G. Sowalsky· 2 shared A. T. Ku· 2 shared B. Capaldo· 2 shared B. J. Capaldo· 2 shared J. Yin· 2 shared M. L. Beshiri· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

K. Kelly

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer

F. Ahmad, M. White, K. Yamamoto, D. R. Crooks, S. Agarwal, Y. Yang, B. Capaldo, S. Raj, A. N. Alilin, A. Ton, S. Adler, J. Seidel, C. Olkowski, M. K. Cherukuri, P. L. Choyke, , J. R. Brender

This study investigates metabolic and imaging phenotypes in prostate cancer linked to RB1 and TP53 loss, finding metabolic changes that may inform multimodal imaging strategies.

bioRxiv · Nov 15, 2023Cancer Biology

Tumor-derived biomarkers beyond antigen expression enhance efficacy of CD276/B7H3 antibody-drug conjugate in metastatic prostate cancer

S. Agarwal, L. Fang, K. McGowen, J. Yin, J. Bowman, A. N. Alilin, A. T. Ku, E. Corey, M. Roudier, L. True, R. Dumpit, I. Coleman, J. Lee, P. S. Nelson, B. J. Capaldo, , K. Kelly

This study identifies biomarkers beyond B7H3 expression that predict response to a B7H3-ADC in metastatic prostate cancer models, improving therapeutic efficacy.

bioRxiv · Apr 19, 2022 · PreprintCancer Biology

The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancer

M. L. Beshiri, B. J. Capaldo, R. Lake, A. T. Ku, D. Burner, C. M. Tice, C. Tran, J. Kostas, A. N. Alilin, J. Yin, S. Agarwal, S. A. Morris, F. H. Karzai, T. L. Lotan, W. L. Dahut, , K. Kelly

This study examines the origin and dynamics of cellular heterogeneity in different subtypes of castrate-resistant prostate cancer using patient-derived organoids and single-cell analyses, identifying distinct lineage plasticity patterns and therapeutic targets.

bioRxiv · Mar 24, 2022 · PreprintCancer Biology

Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor

R. M. Adelaiye-Ogala, B. Gryder, Y. T. M. Nguyen, A. N. Alilin, A. Grayson, K. H. Jansson, M. L. Beshiri, S. Agarwal, B. Capaldo, J. A. Rodriguez-Nieves, K. Kelly, D. J. VanderWeele

This study shows that inhibiting the PI3K/AKT pathway blocks GR induction and overcomes enzalutamide resistance in prostate cancer by remodeling chromatin and enhancing AR activity.

bioRxiv · Oct 1, 2019Cancer Biology